Preparation and in vitro and in vivo evaluations of 10-hydroxycamptothecin liposomes modified with stearyl glycyrrhetinate. (1st January 2019)

• Record Type: Journal Article
• Authors: Zhou, Ting; Tang, Xin; Zhang, Wei; Feng, Jianfang; Wu, Wei
• Is Part Of: Drug delivery. Volume 26:Number 1(2019)
• Page Start: 673
• Page End: 679
• Publication Date: 2019-01-01
• Subjects: 10-hydroxycamptothecin -- stearyl glycyrrhetinate -- liposomes -- pharmacokinetics -- biodistribution; Drug delivery systems -- Periodicals; Drug targeting -- Periodicals; 615.05
• DOI: 10.1080/10717544.2019.1636422
• Languages: English
• ISSNs: 1071-7544

Abstract

Abstract: 10-Hydroxycamptothecin (HCPT) liposomes surface modified with stearyl glycyrrhetinate (SG) were prepared by the film dispersion method. Characterization of the liposomes, including drug release in vitro, pharmacokinetics and tissue distribution, was done. HCPT in plasma and tissues was determined by high-performance liquid chromatography (HPLC). Compared with the conventional HCPT-liposomes and commercially available hydroxycamptothecin injection (HCPT Inject), pharmacokinetic parameters indicated that SG-HCPT-liposomes had better bioavailability. Regarding tissue distribution, the concentration of HCPT loaded by SG modified liposomes in the liver was higher than other tissues and the risk to the kidney was lower than HCPT-liposomes and HCPT Inject. These results support the hypothesis that the HCPT-liposomes modified with SG show enhanced liver-targeting through the glycyrrhetinic acid (GA) receptor to be an efficient drug carrier, which may help to improve therapeutic methods for hepatic diseases in the future.